Pharmaceutical Management Agency New Zealand Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

September 2019

Cumulative for August and September 2019



Contents

Summary of decisions effective 1 September 2019	3
Section H changes to Part II	5
Index	20

Summary of decisions EFFECTIVE 1 SEPTEMBER 2019

- Adalimumab inj 20 mg per 0.4 ml syringe and inj 40 mg per ml 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen) – amended restriction criteria
- Adenosine (Adenocor) inj 3 mg per ml, 2 ml vial new listing and addition of HSS
- Amiodarone hydrochloride (Max Health) inj 50 mg per ml, 3 ml ampoule
 new listing and addition of HSS
- Amiodarone hydrochloride (Cordarone-X and Lodi) inj 50 mg per ml, 3 ml ampoule – to be delisted 1 February 2020
- Amisulpride (Solian) oral liq 100 mg per ml, 60 ml to be delisted 1 July 2020
- Aspirin (Ethics Aspirin EC) tab 100 mg price increase
- Calcium carbonate tab eff 1.75 g (1 g elemental) new listing
- Carbachol inj 150 mcg vial new listing
- Carmustine (Bicnu Heritage) inj 100 mg vial new listing
- Cetomacrogol with glycerol (healthE) crm 90% with glycerol 10%, 100 g
 price decrease, addition of HSS and note
- Chlortalidone [chlorthalidone] (Hygrton) tab 25 mg price decrease and addition of HSS
- Cilazapril (Zapril) tab 2.5 mg and 5 mg new listing and addition of HSS
- Cilazapril (Apo-Cilazapril) tab 2.5 mg and 5 mg to be delisted 1 February 2020
- \bullet Clarithromycin (Klacid) grans for oral liq 50 mg per ml price increase
- Dexrazoxane (e.g. Cardioxane) inj 500 mg new listing
- Erythromycin (as lactobionate) (Erythrocin IV) inj 1 g vial price decrease and addition of HSS
- Flecainide acetate (Flecainide BNM) tab 50 mg new listing and addition of HSS
- Flecainide acetate (Tambocor) tab 50 mg to be delisted 1 February 2020
- Infliximab (Remicade) inj 100 mg amended restriction criteria
- Ketamine (Biomed) inj 1 mg per ml, 100 ml bag, 10 pack and inj 10 mg per ml, 10 ml syringe, 5 pack – new pack size listing and addition of HSS
- Ketamine (Biomed) inj 1 mg per ml, 100 ml bag, 1 pack and inj 10 mg per ml, 10 ml syringe, 1 pack – single pack to be delisted 1 February 2020
- Lysine acetylsalicylate [lysine aspirin] (e.g. Aspegic) inj 500 mg
 amended chemical name

Summary of decisions – effective 1 September 2019 (continued)

- Medroxyprogesterone acetate (Depo-Provera) inj 150 mg per ml, 1 ml syringe
 price increase and addition of HSS
- Nicorandil (Ikorel) tab 10 mg and 20 mg price decrease and addition of HSS
- Noradrenaline inj 0.1 mg per ml, 50 ml syringe new listing
- Oxaliplatin (Oxaliplatin Accord) inj 5 mg per ml, 20 ml vial new listing
- Oxaliplatin (Oxaliccord) inj 5 mg per ml, 20 ml vial to be delisted 1 February 2020
- Povidone iodine (Riodine) soln 10%, 100 ml price decrease and addition of HSS
- Propofol (Fresofol 1% MCT/LCT) inj 10 mg per ml, 20 ml ampoule
 amended presentation description
- Raltegravir potassium (Isentress HD) tab 600 mg new listing
- Sildenafil tab 25 mg, 50 mg and 100 mg (Vedafil) and inj 0.8 mg per ml,
 12.5 ml vial amended restriction criteria
- Sucrose (Biomed) oral liq 25%, 25 ml new listing and addition of HSS
- Sulfasalazine (Salazopyrin EN) tab EC 500 mg price increase and addition of HSS
- Sumatriptan (Clustran) inj 12 mg per ml, 0.5 ml prefilled pen price increase
- Tacrolimus (Tacrolimus Sandoz) cap 0.75 mg new listing
- Tacrolimus (Tacrolimus Sandoz) cap 0.5 mg 1 mg and 5 mg price decrease
- Water (Fresenius Kabi) inj 20 ml ampoule new listing
- Zinc sulphate (Zincaps) cap 137.4 mg (50 mg elemental) addition of HSS

Section H changes to Part II

Effective 1 September 2019

ALIMENTARY TRACT AND METABOLISM

	CITETACAL ATINE (A price and addition of LICC)		
6	SULFASALAZINE († price and addition of HSS) Tab EC 500 mg – 1% DV Dec-19 to 2022 15.53	100	Salazopyrin EN
17	CALCIUM CARBONATE (new listing) Tab eff 1.75 g (1 g elemental)		
18	ZINC SULPHATE (addition of HSS) Cap 137.4 mg (50 mg elemental) – 1% DV Dec-19 to 2022 11.00	100	Zincaps
BLOC	DD AND BLOOD FORMING ORGANS		
31	ASPIRIN († price) Tab 100 mg1.95	90	Ethics Aspirin EC
31	LYSINE ACETYLSALICYLATE [LYSINE ASPIRIN] (amended chemical name) $\pmb{\rightarrow}$ Inj 500 mg		e.g. Aspegic
35	WATER (new listing) Inj 20 ml ampoule	20	Fresenius Kabi
CARI	DIOVASCULAR SYSTEM		
37	CILAZAPRIL (brand change) Tab 2.5 mg – 1% DV Feb-20 to 2022	90 90 20.	Zapril Zapril
39	ADENOSINE (new listing) Inj 3 mg per ml, 2 ml vial – 1% DV Feb-20 to 2022	6	Adenocor
39	AMIODARONE HYDROCHLORIDE (brand change) Inj 50 mg per ml, 3 ml ampoule – 1% DV Feb-20 to 202216.37 Note – Cordarone-X and Lodi inj 50 mg per ml, 3 ml ampoule to be delisted fi	10 rom 1 Febru	Max Health ary 2020.
39	FLECAINIDE ACETATE (brand change) Tab 50 mg – 1% DV Feb-20 to 202219.95 Note – Tambocor tab 50 mg to be delisted from 1 February 2020.	60	Flecainide BNM
44	CHLORTALIDONE [CHLORTHALIDONE] (‡ price and addition of HSS) Tab 25 mg – 1% DV Dec-19 to 2022	50	Hygroton
47	NORADRENALINE (new listing) Inj 0.1 mg per ml, 50 ml syringe		

	Price (ex man. Excl.	GST)	Brand or Generic
	\$	Per	Manufacturer
Char	nges to Section H Part II – effective 1 September 2019 (co	ontinued)	
47	NICORANDIL (↓ price and addition of HSS) Tab 10 mg – 1% DV Dec-19 to 2022	60 60	lkorel Ikorel
49	SILDENAFIL (amended restriction – affected criteria shown only) → Tab 25 mg – 1% DV Sep-18 to 2021	4 4 12	Vedafil Vedafil Vedafil
	 For use in weaning patients from inhaled nitric oxide; or For perioperative use in cardiac surgery patients; or For use in intensive care as an alternative to nitric oxide; or For use in the treatment of erectile dysfunction secondary to spinal in a spinal unit. 	cord injury in	patients being treated
DERI	MATOLOGICALS		
53	CETOMACROGOL WITH GLYCEROL (‡ price, addition of HSS and note) Crm 90% with glycerol 10% – 1% DV Dec-19 to 2022	100 g	healthE
GENI	TO-URINARY SYSTEM		
58	MEDROXYPROGESTERONE ACETATE († price and addition of HSS) Inj 150 mg per ml, 1 ml syringe – 1% DV Dec-19 to 20227.98	1	Depo-Provera
INFE	CTIONS		
75	CLARITHROMYCIN (↑ price) → Grans for oral liq 50 mg per ml192.00	50 ml	Klacid
75	ERYTHROMYCIN (AS LACTOBIONATE) (\$\frac{1}{2}\$ price and addition of HSS) Inj 1 g vial - 1% DV Dec-19 to 202210.00	1	Erythrocin IV
88	RALTEGRAVIR POTASSIUM (new listing) → Tab 600 mg1,090.00	60	Isentress HD
NER\	OUS SYSTEM		
104	KETAMINE (pack size change) Inj 1 mg per ml, 100 ml bag – 1% DV Feb-20 to 2022 270.00 Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022 70.00 Note – Biomed inj 1 mg per ml, 100 ml bag; 1 pack and inj 10 mg per ml from 1 February 2020.	10 5 , 10 ml syring	Biomed Biomed e; 1 pack to be delisted

		Price (ex man. Excl. 6 \$	SST) Per	Brand or Generic Manufacturer
Char	nges to Section H Part II – effective 1 Septer	mber 2019 (con	tinued)	
104	PROPOFOL (amended presentation description) Inj 10 mg per ml, 20 ml vial ampoule – 10% DV Dec-19 to 2022	4.35	5	Fresofol 1% MCT/LCT
108	SUCROSE (new listing) Oral liq 25% – 1% DV Feb-20 to 2022	13.00	25 ml	Biomed
115	SUMATRIPTAN († price) Inj 12 mg per ml, 0.5 ml prefilled pen	81.15	2	Clustran
117	AMISULPRIDE (delisting) Oral liq 100 mg per ml Note – Solian oral liq 100 mg per ml to be delisted from		60 ml	Solian
ONC	DLOGY AGENTS AND IMMUNOSUPPRESSANT	s		
129	CARMUSTINE (new listing) Inj 100 mg vial	1,387.00	1	Bicnu Heritage
136	OXALIPLATIN (brand change) Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021 Note – Oxaliccord inj 5 mg per ml, 20 ml vial to be delis		1 y 2020.	Oxaliplatin Accord
142	DEXRAZOXANE (new listing) → Inj 500 mg			e.g. Cardioxane
	Restricted Initiation Medical oncologist, paediatric oncologist, haematologis All of the following: Patient is to receive treatment with high dose anthrace Based on current treatment plan, patient's cumulative doxorubicin equivalent or greater; and Dexrazoxane to be administered only whilst on anthrace Hither: A.1 Treatment to be used as a cardioprotectant for	cycline given with c e lifetime dose of ar acycline treatment; a child or young adı	urative intent othracycline and ult; or	
145	4.2 Treatment to be used as a cardioprotectant for	secondary mangnar	icy.	
140	TACROLIMUS (new listing) → Cap 0.75 mg	99.30	100	Tacrolimus Sandoz
145	TACROLIMUS (↓ price) → Cap 0.5 mg → Cap 1 mg → Cap 5 mg	84.30	100 100 50	Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz

Price		Brand or
(ex man. Excl. G	ST)	Generic
\$	Per	Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued)

151 ADALIMUMAB (amended restriction – new criteria shown only)

→ Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
→ Inj 40 mg per 0.8 ml pen	1,599.96	2	HumiraPen
→ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira

Restricted

Initiation – severe ocular inflammation

Re-assessment required after 4 months

Either

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Both

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses: or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old: and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 4 months

Either

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation: or
- 2 Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

continued...

Price (ex man. Excl. GST) \$ Per Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued) continued...

- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation Re-assessment required after 12 months

Both

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

160 INFLIXIMAB (amended restriction criteria – affected criteria shown only)

→ Inj 100 mg - 10% DV Mar-15 to 29 Feb 2020806.00 1 Remicade

Initiation - severe ocular inflammation

Re-assessment required after 3 doses

Either

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
- 2 Fither Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Either Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - **2.**2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses: or
- 2 Following each 12-month treatment period, 7the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

continued...

Price (ex man. Excl. GST) \$ Per Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 September 2019 (continued)

3 **Following each 12-month treatment period,** 7the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 3 doses

Both Either

- **1** Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or
- 2 Fither Both:
 - 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
 - 2.2 Either Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective: or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, 7the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 **Following each 12-month treatment period,** 7the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

SENSORY ORGANS

200 CARBACHOL (new listing) Inj 150 mcg vial

VARIOUS

Price	
(ex man. Excl. GST)	
\$	Per

Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019

ALIMENTARY TRACT AND METABOLISM

6	HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE (new listing)
	Topical aerosol foam, 1% with pramoxine hydrochloride 1%

7	RANITIDINE († price) Inj 25 mg per ml, 2 ml ampoule	13.40	5	Zantac
12	LACTULOSE († price and addition of HSS) Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022	3.33	500 ml	Laevolac
12	SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE († p	orice and a	ddition of HS	S)
	9 mg per ml, 5 ml – 1% DV Nov-19 to 2022	29.98	50	Micolette
18	FERROUS SULPHATE SULFATE (amended chemical name, † pric Oral liq 30 mg (6 mg elemental) per ml	e and addi	tion of HSS)	
	– 1% DV Nov-19 to 2022	12.08	500 ml	Ferodan
18	IRON POLYMALTOSE (new listing) Inj 50 mg per ml, 2 ml ampoule	15.22	5	Ferrum H
19	HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] (new listing) Inj 20 mg per ml)		
21	PYRIDOXINE HYDROCHLORIDE (new listing)			

Inj 100 mg per ml, 2 ml vial

31 LYSINE ACETYLSALICYLATE (new listing)

→ Inj 500 mg

e.g. Aspegic

Restricted Initiation Both:

- 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and
- 2 Administration of oral aspirin would delay the procedure.

BLOOD AND BLOOD FORMING ORGANS

29 DALTEPARIN (delisting)

Inj 2,500 iu in 0.2 ml syringe	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe	77.55	10	Fragmin

Note – Fragmin inj 2,500 iu in 0.2 ml syringe, 5,000 iu in 0.2 ml syringe, 7,500 iu in 0.75 ml syringe and 10,000 iu in 1 ml syringe to be delisted from 1 April 2020.

	(Price ex man. Excl. G \$	ST) Per	Brand or Generic Manufacturer
Cha	nges to Section H Part II – effective 1 August 2	019 (continue	d)	
29	DALTEPARIN (delisting)			
	Inj 12,500 iù in 0.5 ml syringe		10	Fragmin
	Inj 15,000 iu in 0.6 ml syringe Inj 18,000 iu in 0.72 ml syringe		10 10	Fragmin Fragmin
	Note – Fragmin inj 12,500 iu in 0.5 ml syringe, 15,000 iu in be delisted from 1 January 2020.			
30	WARFARIN SODIUM († price)			
	Tab 1 mg		100	Marevan
	Tab 3 mg		100	Marevan
	Tab 5 mg	13.50	100	Marevan
31	ASPIRIN (4 price and addition of HSS) Tab 100 mg – 10% DV Nov-19 to 2022	10.80	990	Ethics Aspirin EC
CAR	DIOVASCULAR SYSTEM			
38	PHENOXYBENZAMINE HYDROCHLORIDE (new listing) Inj 50 mg per ml, 1 ml ampoule			
39	DIGOXIN († price and addition of HSS) Tab 62.5 mcg – 1% DV Nov-19 to 2022 Tab 250 mcg – 1% DV Nov-19 to 2022		240 240	Lanoxin PG Lanoxin
41	LABETALOL (delisted) Tab 400 mg Note – labetalol tab 400 mg delisted 1 August 2019.			
43	FUROSEMIDE [FRUSEMIDE] (brand change) Tab 40 mg – 1% DV Dec-19 to 2022 Note – Diurin 40 tab 40 mg to be delisted from 1 December		1,000	Apo-Furosemide
43	FUROSEMIDE [FRUSEMIDE] (new listing) Oral liq 10 mg per ml – 1% DV Jan-20 to 2022 Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 202		30 ml 6	Lasix Lasix
44	SPIRONOLACTONE († price and addition of HSS) Oral liq 5 mg per ml – 1% DV Nov-19 to 2022	30.60	25 ml	Biomed
50	ILOPROST (brand change) Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022 Note – llomedin inj 50 mcg in 0.5 ml ampoule to be delisted		5 / 2020.	Clinect
DER	MATOLOGICALS			
54	CLOBETASOL PROPIONATE (\$\frac{1}{2}\) price and addition of HSS) Crm 0.05% - 1% DV Nov-19 to 2022 Oint 0.05% - 1% DV Nov-19 to 2022		30 g 30 g	Dermol Dermol

		Price (ex man. Excl. G	(T2	Brand or Generic
		\$	Per	Manufacturer
Cha	nges to Section H Part II – effective 1 August	2019 (continue	ed)	
55	CLOBETASOL PROPIONATE (‡ price and addition of HSS) Scalp app 0.05% – 1% DV Nov-19 to 2022		30 ml	Dermol
GEN	ITO-URINARY SYSTEM			
58	INTRA-UTERINE DEVICE (\$\psi\$ price and addition of HSS) IUD 29.1 mm length \$\times\$ 23.2 mm width - 1% DV Nov-19 to 2022 IUD 33.6 mm length \$\times\$ 29.9 mm width - 1% DV Nov-19 to 2022		1	Choice TT380 Short
	IUD 35.5 mm length × 19.6 mm width - 1% DV Nov-19 to 2022		1	Standard Choice Load 375
INF	ECTIONS			
73	CEFALEXIN (‡ price and addition of HSS) Cap 250 mg – 1% DV Nov-19 to 2022	3.33	20	Cephalexin ABM
73	CEFUROXIME († price and addition of HSS) Tab 250 mg – 1% DV Feb-20 to 2022	45.93	50	Zinnat
73	CEFTRIAXONE (brand change) Inj 500 mg vial – 1% DV Jan-20 to 2022 Inj 1 g vial – 1% DV Jan-20 to 2022 Note – DEVA inj 500 mg and 1 g vial to be delisted from 1	3.99	1 5	Ceftriaxone-AFT Ceftriaxone-AFT
73	CEFTRIAXONE (1 price and addition of HSS) Inj 2 g vial – 1% DV Jan-20 to 2022	1.98	1	Ceftriaxone-AFT
75	ROXITHROMYCIN († price) → Tab dispersible 50 mg	8.29	10	Rulide D
80	ITRACONAZOLE († price and addition of HSS) → Cap 100 mg – 1% DV Nov-19 to 2022	4.27	15	ltrazole
84	PENTAMIDINE ISETHIONATE († price and addition of HSS → Inj 300 mg vial – 1% DV Nov-19 to 2022		5	Pentacarinat
MUS	CULOSKELETAL SYSTEM			
94	PYRIDOSTIGMINE BROMIDE († price and addition of HSS Tab 60 mg – 1% DV Nov-19 to 2022		100	Mestinon

	Price		Brand or
(e	(ex man. Excl. GST)		Generic
	\$	Per	Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

NERVOUS SYSTEM

104	KETAMINE (new listing) Inj 100 mg per ml, 2 ml vial155.60	5	Ketamine-Claris
105	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL († price and addition of	HSS)	
	Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 225.00	10	Bupafen
	Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-19 to 2022 235.00	10	Bupafen
106	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE († price and addition of HSS) Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 20228.25	25	Lidocaine-Claris
106	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE († price a Inj 1% with adrenaline 1:100,000, 5 ml ampoule	and addition	of HSS)
	- 1% DV Nov-19 to 202229.00	10	Xylocaine
107	PARACETAMOL († price and addition of HSS)	00	Diamad
	Suppos 25 mg – 1% DV Nov-19 to 2022	20 20	Biomed Biomed
108	FENTANYL († price and addition of HSS)		
	Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022 220.00	10	Biomed
112	ETHOSUXIMIDE (pack size change) Cap 250 mg140.88 Note – the 200 tab pack (Pharmacode 208876) to be delisted from 1 Nover	100 mber 2019.	Zarontin
117	AMISULPRIDE († price and addition of HSS)		
	Tab 100 mg – 1% DV Nov-19 to 2022	30 60	Sulprix Sulprix
117	CHLORPROMAZINE HYDROCHLORIDE (new listing)		
	Tab 10 mg – 1% DV Jan-20 to 2022 14.83 Tab 25 mg – 1% DV Jan-20 to 2022 15.62	100 100	Largactil Largactil
	Tab 100 mg – 1% DV Jan-20 to 202236. 73 Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022 30.79	100 10	Largactil Largactil
ONC	DLOGY AGENTS AND IMMUNOSUPPRESSANTS		
120	FLUDADADINE DUOCDUATE (A price and addition of UCC)		
130	FLUDARABINE PHOSPHATE († price and addition of HSS) Inj 50 mg vial – 1% DV Nov-19 to 2022 576.45	5	Fludarabine Ebewe
142	CALCIUM FOLINATE († price and addition of HSS) Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 20229.49	1	Calcium Folinate
	Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022 25.14	1	Sandoz Calcium Folinate Sandoz

Price		Brand or
(ex man. Excl. G	ST)	Generic
\$	Per	Manufacturer

Changes to Section H Part II - effective 1 August 2019 (continued)

142	CALCIUM FOLINATE (delisting) Inj 10 mg per ml, 10 ml vial		Calcium Folinate Ebewe ary 2020.
142	MESNA († price and addition of HSS)		
	Tab 400 mg – 1% DV Nov-19 to 2022	50	Uromitexan
	Tab 600 mg – 1% DV Nov-19 to 2022	50	Uromitexan
	Inj 100 mg per ml, 4 ml ampoule – 1% DV Nov-19 to 2022 177.45	15	Uromitexan
	Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022 407.40	15	Uromitexan
151	ADALIMUMAB (amended restriction criteria – new criteria shown only)		
	→ Inj 20 mg per 0.4 ml syringe	2	Humira
	→ Inj 40 mg per 0.8 ml pen	2	HumiraPen
	→ Inj 40 mg per 0.8 ml syringe	2	Humira

Restricted

Initiation - severe Behcet's disease

Any relevant practitioner

Re-assessment required after 3 months

All of the following:

- 1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
 - 2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
- 3 The patient is experiencing significant loss of quality of life; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7

Continuation - severe Behcet's disease

Any relevant practitioner

Re-assessment required after 6 months

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Changes to Section H Part II – effective 1 August 2019 (continued)

159 BEVACIZUMAB (amended restriction criteria)

- → Inj 25 mg per ml, 4 ml vial
- → Inj 25 mg per ml, 16 ml vial

Restricted

Initiation - Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months

All of the following:

- 1 Maximum of 6 doses: and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The treatment is for intra-lesional administration

Continuation – Recurrent Respiratory Papillomatosis

Otolarvngologist

Re-assessment required after 12 months

All of the following:

- 1 Maximum of 6 doses: and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initiation - ocular conditions

Fither:

- 1 Ocular neovascularisation: or
- 2 Exudative ocular angiopathy.

169 RITUXIMAB (amended restriction criteria – new criteria shown only)

→	Inj 10 mg per ml,	10 ml vial	1	,075.50	2	Mabthera
→	Inj 10 mg per ml,	50 ml vial	2	,688.30	1	Mabthera

Restricted

Initiation - Neuromyelitis Optica Spectrum Disorde (NMOSD)

Relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Re-assessment required after 6 months

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Continuation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

continued...

Price	
(ex man. Excl. GS	ST)
\$	Per

Brand or Generic Manufacturer

Changes to Section H Part II - effective 1 August 2019 (continued)

continued...

Initiation - Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a neurologist.

Re-assessment required after 2 years

Both

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation - Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a neurologist.

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:

186

- 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
- 3.2 Both

Δ7ΔΤΗΙΟΡΒΙΝΕ (brand change)

- 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
- 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

100	Tab 25 mg – 1% DV Jan-20 to 2022	60 100	Azamun Azamun
186	AZATHIOPRINE († price and addition of HSS) Inj 50 mg vial – 1% DV Nov-19 to 2022 199.00	1	lmuran
RESP	IRATORY SYSTEM AND ALLERGIES		
189	CETIRIZINE HYDROCHLORIDE († price and addition of HSS) Tab 10 mg – 1% DV Nov-19 to 2022 1.12	100	Zista
189	IPRATROPIUM BROMIDE († price and addition of HSS) Nebuliser soln 250 mcg per ml, 2 ml ampoule - 1% DV Jan-20 to 202211.73	20	Univent
193	MONTELUKAST (brand change) Tab 4 mg – 1% DV Jan-20 to 2022	28 28 2020.	Montelukast Mylan Montelukast Mylan

	Pric (ex man. E \$		GST) Per	Brand or Generic Manufacturer
Char	nges to Section H Part II – effective 1 August 2019 (con	tinu	ed)	
194	CAFFEINE CITRATE († price and addition of HSS) Oral liq 20 mg per ml (caffeine 10 mg per ml) - 1% DV Nov-19 to 2022		25 ml 5	Biomed Biomed
194	THEOPHYLLINE (new listing) Tab long-acting 250 mg – 1% DV Jan-20 to 2022		100 500 ml	Nuelin-SR Nuelin
194	SODIUM CHLORIDE († price and addition of HSS) Nebuliser soln 7%, 90 ml bottle – 1% DV Nov-19 to 202224.5	50	90 ml	Biomed
SENS	SORY ORGANS			
196	CHLORAMPHENICOL (addition of HSS) Eye drops 0.5% – 1% DV Nov-19 to 20221.5	54	10 ml	Chlorafast
198	SODIUM CROMOGLICATE (new listing) Eye drops 2% – 1% DV Jan-20 to 2022	79	5 ml	Rexacrom
200	TIMOLOL (delisting) Eye drops 0.25%, gel forming		2.5 ml nuary 2020.	Timoptol XE
EXTE	MPORANEOUSLY COMPOUNDED PREPARATIONS			
211	COAL TAR († price and addition of HSS) Soln BP – 1% DV Nov-19 to 2022	25	200 ml	Midwest
212	MAGNESIUM HYDROXIDE (new listing) Suspension			
212	SODIUM BICARBONATE (new listing) Powder BP – 1% DV Jan-20 to 202210.0	05	500 g	Midwest
213	SYRUP (pack size change) Liq (pharmaceutical grade) – 1% DV Jan-20 to 202214.8		500 ml	Midwest

Note – Midwest liq (pharmaceutical grade), 2,000 ml bottle pack to be delisted from 1 January 2020.

Price	
(ex man. Excl. GS	ST)
\$	Per

Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 August 2019 (continued)

VACCINES

HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (amended restriction criteria – new criteria shown only)

Restricted

Initiation - (Recurrent Respiratory Papillomatosis)

All of the following:

- 1 Either:
 - 1.1 Maximum of two doses for children aged 14 years and under; or
 - 1.2 Maximum of three doses for people aged 15 years and over.
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The patient has not previously had an HPV vaccine.

Index

Pharmaceuticals and brands

Adalmanba Adalencor Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Bethics Aspirin EC. 5 Ethiosuxmide 5 Ethiosuxmide 1 Apo-Furosemide 7, 14 Fernany Aspegic 5, 11 Asperine 17 Azamun 17 Betrious sulfate 17 Ferrous sulfate 17 Ferrous sulfate 17 Ferrous sulfate 18 Ferrous sulfate 19 Ferrous sulfate 11 Ferrous sulfa	A	E	
Adenosine. 5 5 Ethics Aspirin EC. 5 1, 1 Amiodarone hydrochloride. 5 5 Ethoswimide 1 4 Amisulpride. 7, 14 F	Adalimumab 8, 15	Erythrocin IV	6
Amiodarone hydrochloride. 5 Ethosuximide 1: Amisulpride. 7, 14 F Apo-Furosemide. 7, 14 F Apo-Furosemide. 12 Fentanyl 1: Aspegic 5, 11 Ferodan 1: Aspegic 5, 11 Ferodan 1: Asperin 5, 12 Ferrous sulphate 1: Azarmun 17 Ferrous sulphate 1: Azarmun 18 Flecainide acetate. 9 Flecainide acetate. 9 Flecainide BNM 1: Bupracaine hydrochloride with fentanyl 14 Fludarabine Ebewe 1: Acafeine citrate 18 Fresofol 1% MCT/LCT 1: Caffeine citrate 18 Fresofol 1% MCT/LCT 1: Calcium Folinate Ebewe 15 G Calcium Folinate Ebewe 15 G Calcium Folinate Sandoz 14 Gardasil 9 1: Cardoxane. 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Cardoxane. 7 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 14 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 34, 45, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 34, 45, 52 and 58) vaccine [HPV] 1: Ceftalexin 16 Humira Papillomavirus (7, 11, 12, 13, 14, 14, 14, 14, 14, 14,	Adenocor 5		
Amiodarone hydrochloride. 5 Ethosuximide 1: Amisulpride. 7, 14 F Apo-Furosemide. 7, 14 F Apo-Furosemide. 12 Fentanyl 1: Aspegic 5, 11 Ferodan 1: Aspegic 5, 11 Ferodan 1: Asperin 5, 12 Ferrous sulphate 1: Azarmun 17 Ferrous sulphate 1: Azarmun 18 Flecainide acetate. 9 Flecainide acetate. 9 Flecainide BNM 1: Bupracaine hydrochloride with fentanyl 14 Fludarabine Ebewe 1: Acafeine citrate 18 Fresofol 1% MCT/LCT 1: Caffeine citrate 18 Fresofol 1% MCT/LCT 1: Calcium Folinate Ebewe 15 G Calcium Folinate Ebewe 15 G Calcium Folinate Sandoz 14 Gardasil 9 1: Cardoxane. 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Cardoxane. 7 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 13 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 14 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 44, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 34, 45, 52 and 58) vaccine [HPV] 1: Ceftalexin 15 Humira Papillomavirus (6, 11, 16, 18, 31, 33, 34, 45, 52 and 58) vaccine [HPV] 1: Ceftalexin 16 Humira Papillomavirus (7, 11, 12, 13, 14, 14, 14, 14, 14, 14,		Ethics Aspirin EC	12
Apo-Furosemide. 12 Fentanyl. 1. Aspegic 5, 11 Ferodan 1 1 Aspegic 5, 11 Ferodan 1 1 Ferrous sulfate 6 Ferrous sulfate 6 Ferrous sulfate 6 Ferrous sulfate 6 Industriant 6 Industrian	Amiodarone hydrochloride 5	Ethosuximide 1	14
Aspergic	Amisulpride 7, 14	F	
Aspergic	Apo-Furosemide	Fentanyl1	14
Azamun	Aspegic 5, 11		
Azathioprine	Aspirin 5, 12	Ferrous sulfate 1	11
Bevacizumab	Azamun 17	Ferrous sulphate 1	11
Bevacizumab 16	Azathioprine	Ferrum H	11
Bupafen	B	Flecainide acetate	5
Bupivacaine hydrochloride with fentanyl 14 C	Bevacizumab	Flecainide BNM	5
Bupivacaine hydrochloride with fentanyl 14 C	Bupafen	Fludarabine Ebewe 1	14
C Fragmin 11, 12 Caffeine citrate 18 Fresofol 1% MCT/LCT 1 Calcium carbonate 5 Frusemide 12 Calcium Folinate 14, 15 Furosemide [Frusemide] 11 Calcium Folinate Ebewe 15 G 16 Carbachol 10 H Gardasil 9 19 Carbachol 10 H Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 11 Cardioxane 7 45, 52 and 58) vaccine [HPV] 11 Ceftaixone 13 HumiraPen 8, 14 Ceftriaxone-AFT 13 HumiraPen 8, 14 Ceftriaxone-AFT 13 Hydrocortisone acetate with 14 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetinzine hydrochloride 17 Hygroton 1 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chlorafast <td></td> <td>Fludarabine phosphate 1</td> <td>14</td>		Fludarabine phosphate 1	14
Caffeine citrate 18 Fresofol 1% MCT/LCT Calcium rathonate 5 Frusemide 11 Calcium Folinate Ebewe 15 G 12 Calcium Folinate Sandoz 14 Gardasil 9 19 Carbachol 10 H Human papillomavirus (6, 11, 16, 18, 31, 33, 20) Carmustine 7 45, 52 and 58) vaccine [HPV] 11 Ceffalexin 13 Humira 8, 14 Ceftriaxone 13 HumiraPen 8, 14 Ceftriaxone-AFT 13 Hydrocortisone acetate with pramoxine hydrochloride with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 9 Cetoroxime 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6			
Calcium carbonate 5 Frusemide 12 Calcium folinate 14, 15 Furosemide [Frusemide] 12 Calcium Folinate Ebewe 15 G Calcium Folinate Sandoz 14 Gardasil 9 19 Carbachol 10 H Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 19 Carmustine 7 45, 52 and 58) vaccine [HPV] 19 Cetriaxone 13 Humira 8, 18 Cettriaxone-AFT 13 HumiraPen 8, 18 Cettroxime 13 Hydrocortisone acetate with lidocaine [Lignocaine] 11 Cetroxime 13 Hydrocortisone acetate with 12 Cetroxime ABM 13 pramoxine hydrochloride 11 Cetromacrogol with glycerol 6 I Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Ikorel 6 <	Caffeine citrate 18		
Calcium folinate 14, 15 Furosemide [Frusemide] 17 Calcium Folinate Ebewe 15 G Carbachol 10 H Cardoxane 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 245, 52 and 58) vaccine [HPV] 15 Carmustine 7 45, 52 and 58) vaccine [HPV] 15 Ceftalexin 13 Humira 8, 11 Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 1 Cefuroxime 13 Hyarocortisone acetate with 1 Cefuroxime 13 Hyarocortisone acetate with 1 Cefuroxime 13 Hyarocortisone acetate with 1 Cetrizian hydrochloride 17 Hygroton 1 Cetrizian hydrochlorid			
Calcium Folinate Ebewe 15 G Calcium Folinate Sandoz 14 Gardasil 9 15 Carbachol 10 H Cardioxane 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 245, 52 and 58) vaccine [HPV] 19 Cermustine 7 45, 52 and 58) vaccine [HPV] 19 Ceflaexin 13 Humira 8, 18 Ceftriaxone 13 HumiraPen 8, 18 Ceftroxime 13 Hyaluronic acid with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with 1 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetroxime hydrochloride 17 Hygroton 9 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 9 Chloramphenicol 18 Ilopromazine hydrochloride 14 Chloramphenicol 18 Ilopromazine hydrochloride 14 Chloratilidone [Chlorthalidone] 5 Infliximab 9 Chloica Load 375 <td></td> <td></td> <td></td>			
Calcium Folinate Sandoz 14 Gardasil 9 15 Carbachol 10 H Cardioxane 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 245, 52 and 58) vaccine [HPV] 11 Carmustine 7 45, 52 and 58) vaccine [HPV] 15 Ceftriaxone 13 Humira 8, 18 Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 17 Cetroxime 13 Hydrocortisone acetate with 16 Cephalexin ABM 13 pramoxine hydrochloride 11 Cetinzine hydrochloride 17 Hygroton 12 Cetomacrogol with glycerol 6 I I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chloramphenicol 18 Iloprost 12 Chloratidone [Chlorthalidone] 5 Inflisimab 9 Chloratidone [Chlorthalidone] 5 Inflisimab 9 Chloratidone [Chlorthalidone] 5 Inflisimab 9	,		_
Carbachol 10 H Cardioxane 7 Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 19 Cefalexin 13 Humira 8, 15 Ceftriaxone 13 HumiraPen 8, 15 Ceftriaxone-AFT 13 Hydrocortisone acetate with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with 1 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 9 Cetomacrogol with glycerol 6 1 Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 1 Chlorthalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone [Chlorthalidone] 5 Infliximab 9 Choice Load 375 13 Ipratropium bromide 11 Choice TT380 Short 13 Iron polymaltose 11		Gardasil 9	19
Cardioxane 7 Human papillomavirus (6, 11, 16, 18, 31, 33, Carmustine 7 45, 52 and 58) vaccine [HPV] 15 Ceflaixin 13 Humira 8, 14 Ceftriaxone 13 HumiraPen 8, 14 Ceftriaxone-AFT 13 Hydrocortisone acetate with lidocaine [Lignocaine] 1 Cefturoxime 13 Hydrocortisone acetate with 1 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 9 Cetomacrogol with glycerol 6 I 1 Chloramphenicol 18 Ikorel 6 Chloramphenicol 18 Iloprost 11 Chloramphenicol 18 Iloprost 11 Chlorthalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidon		Н	
Carmustine 7 45, 52 and 58) vaccine [HPV] 15 Ceflaixin 13 Humira 8, 15 Ceftriaxone 13 HumiraPen 8, 15 Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 17 Cefuroxime 13 Hydrocortisone acetate with 17 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetinzine hydrochloride 17 Hygroton 1 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 1 Chlorpromazine hydrochloride 14 Imuran 1 Chlorpromazine hydrochloride 14 Imuran 1 Chlorthalidone [Chlorthalidone] 5 Infliximab 6 Chlorthalidone [Chlorthalidone] 5 Infra-uterine device 1 Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 C		Human papillomavirus (6, 11, 16, 18, 31, 33,	
Cefalexin 13 Humira 8, 15 Ceftriaxone 13 HumiraPen 8, 15 Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 6 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorapphenicol 18 Iloprost 12 Chlorthalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone 5 Infliximab 9		45 52 and 58) vaccine [HPV] 1	10
Ceftriaxone 13 HumiraPen 8, 19 Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with 1 Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 2 Cetomacrogol with glycerol 6 I Chloramphenicol 18 lkorel 6 Chloramphenicol 18 lloprost 11 Chloramphenicol 18 lloprost 11 Chloramphenicol 14 Imuran 1 Chloramphenicol 13 Infliximab 1			
Ceftriaxone-AFT 13 Hyaluronic acid with lidocaine [Lignocaine] 1 Cefuroxime 13 Hydrocortisone acetate with Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 6 Chlorafast 18 Ikorel 6 Chlorafast 18 Iloprost 12 Chloraphenicol 18 Iloprost 12 Chloraphenicol 14 Imuran 13 Chloraphenicol hydrochloride 14 Imuran 12 Chloraphalidone (Chlorthalidone) 5 Infliximab 6 Chloritalidone (Chlorthalidone) 5 Infliximab 9 Choice Load 375 13 Ipratropium bromide 11 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ket		•	
Cefuroxime 13 Hydrocortisone acetate with Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 6 Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 1 Chlorramphenicol hydrochloride 14 Imuran 1 Chlorramphenicol hydrochloride 14 Imuran 1 Chlorramphenicol hydrochloride 14 Imuran 1 Chlortalidone [Chlorthalidone] 5 Infliximab 6 Chlorthalidone 5 Intra-uterine device 1 Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Cual tar 18 Ketamine-Claris			
Cephalexin ABM 13 pramoxine hydrochloride 1 Cetirizine hydrochloride 17 Hygroton 9 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 11 Chlortalidone [Chlorthalidone] 5 Infliximab 6 Chlortalidone 5 Infliximab 6 Chlore Load 375 13 Ipratropium bromide 11 Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine-Claris 1 D Kacid 1 Depo-Provera			
Cetirizine hydrochloride 17 Hygroton 6 Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 11 Chlortalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone 5 Intra-uterine device 13 Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine 6, 14 Coal tar 18 Ketamine 6, 14 Depo-Provera 6 Labetalol 1 Dermol<			11
Cetomacrogol with glycerol 6 I Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 11 Chlortalidone [Chlorthalidone] 5 Infliximab 6 Chlorthalidone 5 Intra-uterine device 11 Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 1 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 1 Dermol 12, 13 Laculose <td< td=""><td>•</td><td>Hydroton</td><td>5</td></td<>	•	Hydroton	5
Chlorafast 18 Ikorel 6 Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 1 Chlortalidone [Chlorthalidone] 5 Infliximab 6 Chlore Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 1 Clarithromycin 6 Itrazole 1 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 1 D Klacid 6 D Klacid 6 Depo-Provera 6 Labetalol 1 Dermol 12, 13 Lactulose 1 Demol 12, 13 Laculose 1 Digoxin 12 Lanoxin 1 <td>•</td> <td></td> <td>Ĭ</td>	•		Ĭ
Chloramphenicol 18 Iloprost 12 Chlorpromazine hydrochloride 14 Imuran 1 Chlortalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone 5 Intra-uterine device 13 Choice Load 375 13 Ipratropium bromide 11 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 11 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 1 D Klacid 6 D Klacid 6 D Labetalol 1 Dermol 12, 13 Lactulose 1 Dermol 12, 13 Laculose 1 Digoxin 12 Lanoxin 1	0 0,	Ikorel	6
Chlorpromazine hydrochloride 14 Imuran 1 Chlortalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone 5 Intra-uterine device 13 Choice Load 375 13 Ipratropium bromide 17 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 11 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 D Klacid 6 D Klacid 6 Depo-Provera 6 Labetalol 13 Dermol 12, 13 Lactulose 11 Deporazoxane 7 Laevolac 11 Digoxin 12 Lanoxin 12			
Chlortalidone [Chlorthalidone] 5 Infliximab 9 Chlorthalidone 5 Intra-uterine device 13 Choice Load 375 13 Ipratropium bromide 15 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 13 Clarithromycin 6 Itrazole 13 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 D Klacid 6 D Labetalol 12 Dermol 12, 13 Lactulose 1 Dermol 12, 13 Lactulose 1 Digoxin 12 Lanoxin 12	•	•	
Chlorthalidone 5 Intra-uterine device 13 Choice Load 375 13 Ipratropium bromide 17 Choice TT380 Short 13 Iron polymaltose 11 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 11 Clarithromycin 6 Itrazole 11 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 D Klacid 6 D L 1 Depo-Provera 6 Labetalol 15 Dermol 12, 13 Lactulose 11 Dexrazoxane 7 Laevolac 11 Digoxin 12 Lanoxin 12			
Choice Load 375 13 Ipratropium bromide 1 Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 15 Clarithromycin 6 Itrazole 15 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 11 Dermol 12, 13 Lactulose 11 Dexrazoxane 7 Laevolac 11 Digoxin 12 Lanoxin 12			_
Choice TT380 Short 13 Iron polymaltose 1 Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 15 Clarithromycin 6 Itrazole 15 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12			
Choice TT380 Standard 13 Isentress HD 6 Cilazapril 5 Itraconazole 15 Clarithromycin 6 Itrazole 15 Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12		• •	
Cilazapril 5 Itraconazole 1; Clarithromycin 6 Itrazole 1; Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12			
Clarithromycin. 6 Itrazole. 15 Clobetasol propionate. 12, 13 K Clustran. 7 Ketamine. 6, 14 Coal tar. 18 Ketamine-Claris. 14 D Klacid. 6 Dalteparin. 11, 12 L Depo-Provera. 6 Labetalol. 12 Dermol. 12, 13 Lactulose. 1 Dexrazoxane 7 Laevolac. 1 Digoxin. 12 Lanoxin. 12			
Clobetasol propionate 12, 13 K Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12	·		
Clustran 7 Ketamine 6, 14 Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12			
Coal tar 18 Ketamine-Claris 14 D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12			14
D Klacid 6 Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 13 Dexrazoxane 7 Laevolac 13 Digoxin 12 Lanoxin 13			
Dalteparin 11, 12 L Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 13 Dexrazoxane 7 Laevolac 13 Digoxin 12 Lanoxin 13			
Depo-Provera 6 Labetalol 12 Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12			
Dermol 12, 13 Lactulose 1 Dexrazoxane 7 Laevolac 1 Digoxin 12 Lanoxin 12		-	12
Dexrazoxane 7 Laevolac 1° Digoxin 12 Lanoxin 1°	•		
Digoxin	•		
- 3			
LUNONII I U	Digo/iii 12	=	
		Eurovali i G	. 4

Index

Pharmaceuticals and brands

Largactil	14	Riodine	10
Lasix	12	Rituximab	16
Lidocaine-Claris	14	Roxithromycin	13
Lidocaine [Lignocaine] hydrochloride	14	Rulide D	13
Lidocaine [Lignocaine] hydrochloride with		\$	
adrenaline	14	Salazopyrin EN	5
Lignocaine11,	14	Sildenafil	
Lysine acetylsalicylate		Sodium bicarbonate	
Lysine acetylsalicylate [Lysine aspirin]	5	Sodium chloride	18
Lysine aspirin		Sodium citrate with sodium lauryl sulphoacetate	11
M		Sodium cromoglicate	18
Mabthera	16	Solian	
Magnesium hydroxide	18	Spironolactone	12
Marevan		Sucrose	
Medroxyprogesterone acetate	6	Sulfasalazine	5
Mesna		Sulprix	
Mestinon	13	Sumatriptan	
Micolette	11	Syrup	
Montelukast	17	Ť	
Montelukast Mylan	17	Tacrolimus	7
N		Tacrolimus Sandoz	7
Nicorandil	6	Theophylline	
Noradrenaline	5	Timolol	
Nuelin	18	Timoptol XE	18
Nuelin-SR	18	U	
0		Univent	17
Oxaliplatin	7	Uromitexan	15
Oxaliplatin Accord	7	V	
P		Vedafil	6
Paracetamol	14	W	
Pentacarinat	13	Warfarin sodium	12
Pentamidine isethionate	13	Water	5
Phenoxybenzamine hydrochloride	12	X	
Povidone-iodine	10	Xylocaine	14
Propofol	7	Z	
Pyridostigmine bromide	13	Zantac	
Pyridoxine hydrochloride	11	Zapril	5
R		Zarontin	14
Raltegravir potassium	6	Zincaps	
Ranitidine	11	Zinc sulphate	5
Remicade	9	Zinnat	
Rexacrom	18	Zista	17

New Zealand Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1172-3694 (Print) ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

